Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Collegium Pharmaceutical (COLL) has provided an update.
Collegium Pharmaceutical, Inc. finalized its acquisition of Ironshore Therapeutics Inc. on September 3, 2024, with a merger deal valued at approximately $525 million in cash and an additional potential milestone payment of $25 million. To fund this acquisition, Collegium secured a $325 million loan from BioPharma Credit PLC and associated lenders. The completion of the deal was publicly announced via a press release and detailed in a corporate presentation on the company’s website.
Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.